RecruitingPhase 3NCT04666714
Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain
National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain
Sponsor
EMS
Enrollment
136 participants
Start Date
May 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of Praga formulation in the treatment of neuropathic pain.
Eligibility
Min Age: 18 Years
Inclusion Criteria10
- Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;
- Participants of 18 years and older;
- Diagnosis of type 2 or type 1 diabetes for at least 1 year;
- No change in antidiabetic medication winthin 3 months;
- Diagnosis of painful sensorimotor diabetic polyneuropathy;
- Presence of at least one of the following symptoms: i. numbness in the toes, feet and / or legs; ii. paresthesias (tingling and / or neuropathic pain) in the toes, feet and / or legs.
- Presence of at least one of the following signs: i. symmetrical hypoesthesia of tactile, thermal or painful sensation (s) in the distal region of the legs; ii. hypoactive or abolished achilles reflexes;
- Glycated hemoglobin ≤ 11%;
- Score ≥ 12 points on the LANSS pain scale (Leeds Assessment of Neuropathic Symptoms and Signs); j) Participants with moderate to severe pain, a score ≥ 4 on the numerical pain scale (0-10 points);
- Participants with moderate to severe neuropathic pain who recorded in the diary a minimum of 4 of the 7 days from the period to assess the baseline pain score.
Exclusion Criteria14
- Known hypersensitivity to the formula components used during the clinical trial;
- History of alcohol and/or substance abuse within 2 years;
- Pregnant women, breastfeeding or planning to become pregnant, or women with the potential to become pregnant who are not using a reliable method of contraception;
- History of pernicious anemia, uncontrolled hypothyroidism, chronic hepatitis B;
- HIV diagnosis;
- History of neurological disorder unrelated to diabetic neuropathy;
- Non-responders to previous pregabalin treatment;
- High variability in the baseline pain score;
- Other conditions that may alter the sensitivity in the affected dermatome or in the area involved in neuropathic pain that may confuse pain assessment;
- Severe psychiatric condition;
- Cognitive decline that affect the participant from correctly answering the scales and questionnaires;
- Clinically relevant cardiac abnormalities, which at the researcher's discretion represent a risk to participation in the trial;
- Participant who has amputated lower limb due to complications from diabetes;
- Renal failure, defined by the estimated glomerular filtration rate \[eGFR\] <60 mL / min / 1.73 m2.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPraga formulation
Praga formulation tablet
OTHERPlacebo pregabalin 75mg
Placebo pregabalin 75mg tablet
OTHERPlacebo Pregabalin 150mg
Placebo Pregabalin 150mg tablet
DRUGPregabalin 75mg
Pregabalin 75mg tablet
DRUGPregabalin 150mg
Pregabalin 150mg tablet
OTHERPlacebo Praga formulation
Placebo Praga formulation tablet
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04666714
Related Trials
Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
NCT069156621 location
Neuropathic Characteristics of Subacromial Pain Syndrome
NCT070571281 location
Chronic Unilateral Lumbar Radicular Pain
NCT060927491 location
Virtual Reality (VR) Self-Hypnosis Software
NCT063988471 location
Deep rTMS (H-coil) for Neuropathic Pain or Fibromyalgia
NCT062504912 locations